Mobile App

Google Play Apple Store
Integrating Emerging Therapies into Clinical Practice for Pediatric ITP: Exploring Evidence, Guidelines and Best Practices
AMA/ABS/ANCC-Video Presentation
Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disorder marked by reduced platelet counts, purpura, and bleeding episodes driven by antiplatelet autoantibodies. Diagnosis remains one of exclusion, requiring careful differentiation from other causes of thrombocytopenia. Advances in pediatric ITP treatment are ushering in an era of precision medicine, integrating novel immunomodulatory therapies and personalized treatment approaches to optimize patient care. Recent research has introduced targeted pharmacological agents that address immune dysregulation, refining treatment protocols to align with individual patient profiles. The evolving landscape of pediatric ITP care calls for a comprehensive, evidence-driven approach, combining established therapies with innovative strategies to enhance efficacy and long-term disease management.

In this lecture library, Dr. Cindy Neunert, provides expert insights into emerging data on ITP pathophysiology, diagnosis, and treatment, equipping healthcare providers with the knowledge to translate new research into clinical practice and improve pediatric patient care.
Review the activity and claim AMA, ABS, or ANCC credit/contact hour after completion of a brief pretest and posttest/evaluation.




 
Cindy Neunert, MD Cindy Neunert, MD
Division of Pediatric Hematology
Oncology, and Stem Cell Transplantation
Columbia University Irving Medical Center
New York, New York

20
Supported by an independent educational grant from Sobi, Inc.

Launch Date: June 30, 2025
Release Date: June 30, 2025
Expiration Date: May 31, 2026

Mini Module
7942
PED-ITP-1730x162.gif
True
Hematology

CookieConsent

Change Settings